Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Aimovig (erenumab-aooe by Year
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)
Amgen Aimovig (erenumab-aooe: -22.0% in FY2023, down 53.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Aimovig ® | 303 | 20 | 323 | 414 | (22%)”
Source: Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -22.0% | -53.0 pts | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 31.0% | +47.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | -16.0% | -40.0 pts | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 24.0% | – | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
Cite this data
StockData. (2026). Amgen Aimovig (erenumab-aooe (%), annual FY2020–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-aimovig-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.